X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (81) 81
oncology (63) 63
female (51) 51
cancer (49) 49
index medicus (49) 49
male (48) 48
aged (46) 46
lung neoplasms - drug therapy (45) 45
life sciences (44) 44
middle aged (39) 39
carcinoma, non-small-cell lung - drug therapy (37) 37
chemotherapy (37) 37
lung neoplasms - pathology (36) 36
adult (35) 35
respiratory system (35) 35
lung cancer (31) 31
carcinoma, non-small-cell lung - pathology (30) 30
antineoplastic combined chemotherapy protocols - therapeutic use (28) 28
[ sdv.can ] life sciences [q-bio]/cancer (27) 27
lung neoplasms - mortality (26) 26
prognosis (25) 25
survival (25) 25
neoplasm staging (22) 22
surgery (22) 22
survival rate (22) 22
aged, 80 and over (21) 21
carcinoma, non-small-cell lung - mortality (21) 21
lung neoplasms - surgery (19) 19
mesh : humans (19) 19
carcinoma, non-small-cell lung - surgery (18) 18
deoxycytidine - analogs & derivatives (18) 18
lung neoplasms (18) 18
mesh : lung neoplasms (18) 18
non-small cell lung cancer (18) 18
treatment outcome (18) 18
cisplatin (17) 17
disease-free survival (16) 16
lung cancer, non-small cell (16) 16
deoxycytidine - administration & dosage (15) 15
cisplatin - administration & dosage (14) 14
survival analysis (14) 14
carcinoma, non-small-cell lung - therapy (13) 13
lung neoplasms - therapy (13) 13
non-small-cell lung cancer (13) 13
radiotherapy (13) 13
carcinoma, non-small-cell lung (12) 12
combined modality therapy (12) 12
france (12) 12
mesh : carcinoma, non-small-cell lung (12) 12
multivariate analysis (12) 12
research (12) 12
carcinoma (11) 11
care and treatment (11) 11
clinical trials (11) 11
docetaxel (11) 11
human health and pathology (11) 11
lung neoplasms - diagnosis (10) 10
neoadjuvant therapy (10) 10
open-label (10) 10
preoperative chemotherapy (10) 10
prospective studies (10) 10
pulmonology and respiratory tract (10) 10
quality of life (10) 10
antineoplastic agents - therapeutic use (9) 9
carboplatin - administration & dosage (9) 9
chemotherapy, adjuvant (9) 9
gemcitabine (9) 9
hematology, oncology and palliative medicine (9) 9
mesh : aged (9) 9
mesh : female (9) 9
mesh : male (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
carboplatin (8) 8
diagnosis (8) 8
follow-up studies (8) 8
patients (8) 8
proportional hazards models (8) 8
therapy (8) 8
trial (8) 8
vinblastine - analogs & derivatives (8) 8
[sdv.can]life sciences [q-bio]/cancer (7) 7
cancer therapies (7) 7
carcinoma, non-small-cell lung - diagnosis (7) 7
france - epidemiology (7) 7
gefitinib (7) 7
mesh : middle aged (7) 7
mesh : survival rate (7) 7
methodology (7) 7
paclitaxel - administration & dosage (7) 7
phase-iii trial (7) 7
risk factors (7) 7
time factors (7) 7
vinblastine - administration & dosage (7) 7
[ sdv.mhep.psr ] life sciences [q-bio]/human health and pathology/pulmonology and respiratory tract (6) 6
adenocarcinoma (6) 6
adjuvant chemotherapy (6) 6
biomarkers (6) 6
carcinoma, non-small-cell lung - genetics (6) 6
drug therapy (6) 6
epidermal growth factor receptors (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10026, pp. 1415 - 1426
Journal Article
The Lancet Oncology, ISSN 1470-2045, 12/2019, Volume 20, Issue 12, pp. 1619 - 1620
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9796, pp. 1079 - 1088
Summary Background Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell lung cancer (NSCLC) in fit, non-elderly adults, but... 
Internal Medicine | SURVIVAL | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | INTERNATIONAL-SOCIETY | GERIATRIC ASSESSMENT | UNDERREPRESENTATION | OLDER | OUTCOMES | COMBINATION | AGE | COMORBIDITY | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Vinblastine - administration & dosage | Carboplatin - adverse effects | Carcinoma, Squamous Cell - mortality | Vinblastine - analogs & derivatives | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Paclitaxel - administration & dosage | Drug Administration Schedule | Deoxycytidine - administration & dosage | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Survival Rate | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Clinical trials | Chemotherapy | Radiation therapy | Cancer therapies | Adenocarcinoma | Vinblastine | Carcinoma, Non-Small-Cell Lung | Antineoplastic Agents | Antineoplastic Combined Chemotherapy Protocols | Lung Neoplasms | Carcinoma, Squamous Cell | Life Sciences | Deoxycytidine | Paclitaxel | Carboplatin | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 12, pp. 1125 - 1133
Summary Background Chemotherapy is the standard of care for advanced stages of non-small-cell lung cancer (NSCLC). TG4010 is a targeted immunotherapy based on... 
Hematology, Oncology and Palliative Medicine | DOUBLE-BLIND | PROGNOSTIC-FACTORS | GENE | ONCOLOGY | EXPRESSION | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vaccinia virus - genetics | Antimetabolites, Antineoplastic - administration & dosage | Cisplatin - administration & dosage | Cancer Vaccines - therapeutic use | Interleukin-2 - immunology | Time Factors | Adult | Female | Chemotherapy, Adjuvant | Carcinoma, Non-Small-Cell Lung - pathology | Risk Assessment | Deoxycytidine - administration & dosage | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Cancer Vaccines - adverse effects | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Non-Small-Cell Lung - immunology | Disease-Free Survival | Interleukin-2 - genetics | Carcinoma, Non-Small-Cell Lung - therapy | Lung Neoplasms - immunology | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mucin-1 - immunology | Vaccines, Synthetic | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Membrane Glycoproteins - adverse effects | Deoxycytidine - analogs & derivatives | Mucin-1 - genetics | Index Medicus | Interleukin-2 | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Life Sciences | Cancer Vaccines | Membrane Glycoproteins | Antineoplastic Combined Chemotherapy Protocols | Cisplatin | Mucin-1 | Vaccinia virus | Deoxycytidine | Antimetabolites, Antineoplastic | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 212 - 223
Summary Background MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | MVA-MUC1-IL2 | PROSTATE-CANCER | VACCINE | Predictive Value of Tests | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Fatigue - etiology | Male | Cisplatin - administration & dosage | Antigens, CD - analysis | Antigens, Differentiation, T-Lymphocyte - analysis | Neutropenia - etiology | Cancer Vaccines - therapeutic use | Receptors, IgG - analysis | Mucin-1 - analysis | Lectins, C-Type - analysis | Female | Paclitaxel - administration & dosage | Lymphocytes - chemistry | Anemia - etiology | Bevacizumab - administration & dosage | Double-Blind Method | Lung Neoplasms - chemistry | Lymphocyte Activation | CD56 Antigen - analysis | Deoxycytidine - administration & dosage | Erlotinib Hydrochloride - administration & dosage | Carboplatin - administration & dosage | Cancer Vaccines - adverse effects | Lung Neoplasms - therapy | Immunotherapy - adverse effects | Biomarkers, Tumor - blood | Disease-Free Survival | Carcinoma, Non-Small-Cell Lung - therapy | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - administration & dosage | Aged | Membrane Glycoproteins - adverse effects | Deoxycytidine - analogs & derivatives | Antigens | Fc receptors | Hospitals | Interleukins | Immunotherapy | Mucins | Clinical trials | Product development | Lung cancer, Non-small cell | Analysis
Journal Article
Journal Article
Journal Article
Quality of Life Research, ISSN 0962-9343, 1/2015, Volume 24, Issue 1, pp. 5 - 18
Journal Article
Journal of Thoracic Disease, ISSN 2072-1439, 09/2018, Volume 10, Issue Suppl 26, pp. S3043 - S3046
Journal Article
Journal Article
European Respiratory Journal, ISSN 0903-1936, 08/2017, Volume 50, Issue 2, pp. 1700514 - 1700514
Journal Article